Tvaster Genkalp at ISLB 2026

Nov 7–9, 2026 Madrid, Spain ~700 attendees Website

Tvaster Genkalp brings 2 presentations to ISLB 2026 in Madrid. Its work centres on cell-free DNA methylation blood tests for liver cancer. One study reports how Episcreen Liver, which adds AI, performs in screening for hepatocellular carcinoma and following treatment response, and another detects chemotherapy resistance and relapse in childhood liver tumours.

Organization	ISLB 2026 Attendance
TG Tvaster Genkalp Chennai, India
Diagnostics & testing labs Develops cfDNA methylation blood tests, led by Episcreen Liver for hepatocellular carcinoma screening and surveillance.	Talk Mon Nov 9 10:00am–11:30am Part of Preferred Oral Abstract Session Episcreen® Liver: Clinical Performance of a cfDNA Methylation Blood Test with AI Integration for Hepatocellular Carcinoma Screening, Surveillance and Treatment Response Poster Part of Poster sessions Detection of Chemotherapy Resistance and Recurrence in Paediatric Liver Tumors Using a cfDNA Hypermethylation Test: A Pilot Clinical Study ctDNA & MRD · Clinical use

Organization

ISLB 2026 Attendance

Tvaster Genkalp

Chennai, India

Diagnostics & testing labs

Develops cfDNA methylation blood tests, led by Episcreen Liver for hepatocellular carcinoma screening and surveillance.

Talk

Mon Nov 9
10:00am–11:30am

Part of Preferred Oral Abstract Session

Episcreen® Liver: Clinical Performance of a cfDNA Methylation Blood Test with AI Integration for Hepatocellular Carcinoma Screening, Surveillance and Treatment Response

Poster

Part of Poster sessions